SAN
DIEGO, Nov. 7, 2023 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene
therapy company advancing a new class of treatments for patients
with cancer and rare diseases, today announced that the Company
will participate in the following upcoming investor conferences in
November:
Stifel 2023 Healthcare Conference
Date: Tuesday, November 14, 2023
Time: 8:00am ET
Piper Sandler 35th
Annual Healthcare Conference
Date: Thursday, November 30, 2023
Time: 11:00am ET
Webcasts will be available on the Investors & Media Section
of Poseida's website, www.poseida.com. A replay of the webcast will
be available for approximately 90 days following the
presentation.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company advancing differentiated cell and gene therapies with the
capacity to cure certain cancers and rare diseases. The Company's
pipeline includes allogeneic CAR-T cell therapy product candidates
for both solid and liquid tumors as well as in vivo gene therapy
product candidates that address patient populations with high unmet
medical need. The Company's approach to cell and gene therapies is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™
Site-Specific Gene Editing System and nanoparticle and hybrid gene
delivery technologies as well as in-house GMP cell therapy
manufacturing. The Company has formed a global strategic
collaboration with Roche to unlock the promise of cell therapies
for patients with hematological malignancies. Learn more at
www.poseida.com and connect with us on X and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-two-upcoming-investor-conferences-301979425.html
SOURCE Poseida Therapeutics, Inc.
